AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

Spark sells remaining Connexa stake for $314m
Markets

Spark sells remaining Connexa stake for $314m

The sale will result in a $70m gain on telco's books.

Ben Moore 11:45am
Zespri on track for 'moderate increase' in volume next year
Primary Sector

Zespri on track for 'moderate increase' in volume next year

Zespri's producer vote to expand global supply passed this week.

Neal Barclay to exit Meridian as CEO
Markets

Neal Barclay to exit Meridian as CEO

Current CFO Mike Roan will take Barclay's spot atop Meridian.

Todd Corp: what went wrong?
Finance

Todd Corp: what went wrong?

A dividend freeze as the family empire rebuilds for the future.